Replies to post #18181 on DNAprint Genomics (DNAG)

[cosmiclifeform]

Frog...your analysis stands....as pure hypothetical speculation...nothing more.

You absolutely do not have any clue as to what the pps will do tomorrow...or in 6 months.

Until this funding transaction moves forward...no one knows what the future brings and all you offer is negative speculation in the face of exciting possibilities of DNAP's own drug classifiers coming to market, the outcome of the 4 cancer research areas with DNAP/Moffitt that may lead to more cancer drug classifers, and the addition of Biofrontera's dermatology drug pipelines for a potential $2 billion dollar dermatology drug market...

I'll take the exciting possibilities for DNAP over your negative speculation every time..thanks.

God's Speed To DNAP's Vision and To All DNAP Investors,

Robert

[gunnabeoneday]

frog...i didn't check the s2, but if accurate, it must not account for the balance of the shares registered for LJC, etc. So, in reality, it could be 20% of 1.5bill or it could be almost 30% if the 300M is added to the current OS.

I guess you confirmed this with your more recent statement: "It is an interim state in the transaction, before all the shares are allocated". Hence, you're acknowledging future dilution [even to Dutchess] but ignoring the impact to the % ownership to further your unbalanced analysis.


On the $50mill issue, i still maintain you're way off base. Market value has clearly been established by the buyer [dnap] and seller [biofrontera] at approx. $50mill. If another suitor steps forward, rest assured that $50mill is the starting min. value unless something substantive has occurred since the purchase date.....oh ya, it did. Bio acquired a cancer drug...hmmmmm. Positive or negative impact to market value....i won't interject any bias at this stage.